Loading organizations...
§ Angel Group · MA, USA
An angel investment group providing seed and early-stage funding for New England startups, focused on life sciences, software, and B2B tech.
Beacon Angels is a Boston-based angel investment group that provides seed and early-stage funding to fast-growing startups located primarily across the New England region. The organization operates as a member-funded network of accredited investors who pool their personal capital to acquire equity in emerging companies within the healthcare, medical device, life sciences, software, and business-to-business technology sectors. The group typically allocates initial investments ranging from $50,000 to $400,000 per deal, frequently syndicating with other regional investment networks to participate in larger institutional funding rounds. Through its collaborative investment approach, the network has achieved successful exits returning several million dollars in total capital to its members while backing notable portfolio companies such as Pixability, Siamab Therapeutics, ZappRx, and Cognoptix. Beacon Angels was established in 2006 by a group of founders whose specific names remain undisclosed.
Key people at Beacon Angels.
Beacon Angels is a Boston-based angel investment group founded in 2006 that focuses on early-stage, fast-growing companies, typically investing between $50,000 and $400,000 per deal. Their mission is to help entrepreneurs by providing capital and strategic support, primarily targeting startups in sectors such as healthcare, biotechnology, therapeutics, software, and information technology. Beacon Angels has contributed significantly to the New England startup ecosystem by enabling growth and generating multiple successful exits, with returns exceeding invested amounts and an internal rate of return (IRR) that reflects strong portfolio performance[1][2][3].
The group is composed of accredited investors who seek to discover and support promising startups, benefiting from shared capital, experience, and strategic relationships. They meet monthly to review and discuss investment opportunities, fostering a collaborative environment for both investors and entrepreneurs. Beacon Angels' investments tend to focus on U.S.-based companies, with a preference for startups valued between $1 million and $5 million, and they have a track record of 29 investments and 6 exits, primarily in healthcare and biotech sectors[1][2].
Founded by Dan Von Kohorn, Lex Kelso, and William Swiggart, Beacon Angels has evolved to maintain a steady pace of investments, with peak activity around 2012 and continued involvement through 2019. Their investment approach favors companies that have been operating for several years (typically 4-5 years), which may indicate a preference for startups with some established traction or maturity before investment[2].
Beacon Angels rides the trend of early-stage angel investing in innovation-driven sectors like biotech and software, which are critical to the evolving healthcare and technology markets. Their timing aligns with growing demand for seed and early growth capital in the Boston area, a major innovation hub. By supporting startups at formative stages, Beacon Angels helps fuel regional economic growth and innovation, contributing to a vibrant ecosystem where new technologies and therapies can emerge and scale[1][2].
Looking ahead, Beacon Angels is positioned to continue leveraging its strong local network and sector expertise to identify promising startups, especially in healthcare and biotech, where innovation remains robust. Trends such as digital health, personalized medicine, and software-driven solutions will likely shape their investment focus. As the startup ecosystem grows more competitive, Beacon Angels’ collaborative model and proven track record may enhance its influence, helping to bridge the gap between early innovation and scalable business success[1][2][3].
Key people at Beacon Angels.
Beacon Angels has 11 tracked investments across 10 companies. The latest tracked deal is $6.0M Other Equity in Lenoss Medical in March 2026.